Co-Morbidities of Patients with Hypertension Admitted to Amassoma General Hospital, Bayelsa State South-South of Nigeria

Owonaro A. Peter, Eniojukan F Joshua, Owonaro AE Daughter and Ebinyo C Nelson
Additional contact information
Eniojukan F Joshua: Department of Clinical Pharmacy and Pharmacy Practice, Niger Delta University, Nigeria
Ebinyo C Nelson: Skypat Pharmacy limited Yenagoa, Nigeria

Global Journal of Pharmacy & Pharmaceutical Sciences, 2017, vol. 2, issue 4, 86-91

Abstract: The prevalence of Hypertension is on the increase. Hypertensive patients with co-morbidity is more compared to patient living with only hypertension. This study evaluated the prevalence of patient with Hypertension and co morbidity and their effect on the outcome of therapy of Hypertension. The research is a retrospective descriptive study using data obtained from patient’s patients’ case files in General Hospital Amassoma, Bayelsa State. About 50% were male, 30% falls under the age bracket of 45-54 years. Diabetes mellitus was reported to be the most common co morbidity associated with hypertensive patients. About 29.3% of the hypertensive patients had diabetes, 15% had cardiovascular disease, 14.3% had obesity, 13.2% had kidney disease, 11.8% had arthropathy, 2.9% had PUD, 1.1% had dyslipidemia, 1.1% had neuropathy, 0.7% had PID and 0.4% had retinopathy. There was gender variation with patients that had co morbidities. Hence, it is vital to manage Hypertensive patients with co morbidities to reduce high or elevated blood pressure to avert end organ damage due to high blood pressure. However, further studies should be carried out on how patients with hypertension and co morbidities are treated [1].

Keywords: juniper publishers:Journal of Pharmacy; Global Journal of Pharmacy; Pharmaceutical Sciences; Pharmacy & Pharmaceutical Sciences; pharmaceutical sciences journals; omics online; open access; drug discovery; Clinical Trials; juniper publishers open access journals; juniper publishers reivew (search for similar items in EconPapers)
Date: 2017
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/gjpps/pdf/GJPPS.MS.ID.555594.pdf (application/pdf)
https://juniperpublishers.com/gjpps/GJPPS.MS.ID.555594.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jgjpps:v:2:y:2017:i:4:p:86-91

DOI: 10.19080/GJPPS.2017.02.555594

Access Statistics for this article

Global Journal of Pharmacy & Pharmaceutical Sciences is currently edited by Sophia Mathis

More articles in Global Journal of Pharmacy & Pharmaceutical Sciences from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().